In the 2013 American College of Cardiology (ACC)/American Heart Association Guideline (AHA) on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, low-density lipoprotein cholesterol treatment thresholds have been replaced with a focus on global risk. In this context, we re-examine the need for fasting lipid measurements in various clinical scenarios including estimating initial risk for atherosclerotic cardiovascular disease in a primary prevention patient; screening for familial lipid disorders in a patient with a strong family history of premature atherosclerotic cardiovascular disease or genetic dyslipidemia; clarifying a diagnosis of metabolic syndrome so it can be used to make lifestyle counseling more effective; assessing residual risk in a treated patient; diagnosing and treating patients with suspected hypertriglyceridemic pancreatitis; or diagnosing hypertriglyceridemia in patients who require therapy for other conditions that may further elevate triglycerides. Posing a specific question can aid the clinician in understanding when fasting lipids are needed and when nonfasting lipids are adequate. (J Am Coll Cardiol 2016;67:1227-34)
the focus by using 10-year coronary heart disease risk estimation, but still relied on specific LDL-C goals to set treatment thresholds (4). These guidelines therefore reinforced the use of fasting lipids.
Rather than emphasizing specific LDL-C goals, the 2013 guidelines sought to match the intensity of LDL-CÀlowering therapy to the baseline ASCVD risk.
More specifically, they found strong evidence for statins as first-line therapy in patients: 1) with clinical ASCVD; 2) 40 to 75 years of age with diabetes and an LDL-C of 70 to 189 mg/dl; 3) with an LDL-C $190 mg/dl; and 4) 40 to 75 years of age without clinical ASCVD or diabetes, but with an LDL-C of 70 to 189 mg/dl and estimated 10-year ASCVD risk of 7.5% or higher (1) . With this latter group, use of statins was not meant to be automatic, but rather was to be considered after a clinician-patient risk discussion (5 (HDL-C). This is largely due to inaccuracy of the Friedewald formula at low LDL-C (<70 mg/dl) and high triglyceride (>400 mg/dl) levels (8). 
Clinical Scenarios Necessity of Fasting
The 6 questions discussed in this review and the recommendations for fasting or nonfasting lipid measurements for each scenario are presented. *ApoB optional, very helpful for precise diagnosis. †In emergency situations, patients with suspected pancreatitis may be assessed with nonfasting lipids. ApoB ¼ apolipoprotein B; ASCVD ¼ atherosclerotic cardiovascular disease.
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Fasting or Nonfasting Lipid Measurements that going from a 1% risk to a 0.5% risk is akin to a half-the-distance to the goal penalty on first down at the 1-yard line-yes, the result is theoretically better, but really is quite modest. an on-treatment LDL-C <70 mg/dl, nonÀHDL-C <100 mg/dl, or apoB <80 mg/dl (38) . In contrast, on-treatment triglycerides showed no association with cardiovascular disease (39) . Thus, in this trial, nonfasting nonÀHDL-C or apoB levels were as useful as levels obtained in the fasting state.
In secondary prevention, good adherence and an appropriate response to statin therapy are especially A recent AHA statement on hypertriglyceridemia and coronary heart disease suggests that clinicians 
